Advertisement

Topics

Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress

16:10 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through 36 Weeks; Plan to Initiate Phase 3 Trial in the First Half of 2018 -- -- Additional Preclinical Data Demonstrate Potential of...

Other Sources for this Article

Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com

NEXT ARTICLE

More From BioPortfolio on "Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...